Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy for which treatment options have been largely limited to cytotoxic chemotherapy for the past four decades. Next-generation sequencing and other approaches have identified a spectrum of genomic and epigenomic alterations that cont...
Main Authors: | Bettina Wingelhofer, Tim C. P. Somervaille |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00850/full |
Similar Items
-
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
by: Marcelo L. Ribeiro, et al.
Published: (2019-10-01) -
Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation
by: Florian Perner, et al.
Published: (2020-12-01) -
Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
by: Rui Lu, et al.
Published: (2017-10-01) -
Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia
by: Daniela Magliulo, et al.
Published: (2018-07-01) -
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
by: Stuart J Gallagher, et al.
Published: (2015-09-01)